Medicare’s controversial draft decision - released on January 11th of this year - to restrict coverage of Aduhelm to beneficiaries who enroll in post-marketing clinical trials may be the only feasible option left for the product. Such a policy is called coverage with evidence development.
Subscribe to:
Post Comments (Atom)
< + > Proofpoint’s Intelligent Monitoring Catches Both Accidental and Malicious Email Breaches
Proofpoint understands that data breaches can take place through outgoing as well as incoming communications, and through a wide variety of...
No comments:
Post a Comment